Search

everythinglearnresearchcommunity

for

Search:↓

OP has been using daily oral finasteride 1.25mg for 5 months with noticeable progress and no side effects. They chose this dosage by cutting 5mg pills into quarters due to cost.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

Finasteride effectively maintained hairline stability for 11 years with no side effects. Consistency and early treatment were key to success.

The user documented their hair treatment journey from 2018 to 2025, primarily using dutasteride after initially trying topical minoxidil in 2023. They saw noticeable regrowth in the temple area after two months and experienced some shedding after stopping minoxidil.

Young individuals with seemingly healthy hairlines are using treatments like finasteride, dutasteride, and minoxidil, possibly due to paranoia or proactive prevention of hair loss. Some believe social media influences this behavior, while others argue for waiting until actual hair loss begins before starting treatment.

Discontinuing Minoxidil typically returns hair to baseline, but some believe it may go below baseline temporarily. Continuing finasteride or dutasteride is recommended.

The conversation is about finding a cheaper source for RU58841, with a suggestion to use Chemyo. One user suggests that RU58841 may not be necessary.

The user has been using minoxidil, dutasteride, and microneedling for hair loss but has noticed accelerated thinning at the crown and hairline recently. They plan to start using Nizoral and have a dermatologist appointment soon.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

The user experienced significant hair regrowth over five months using Locklabs oral tablets, with no side effects and only a minor shed. They dye their hair black to cover natural blonde, which may affect perceived hair density.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

The conversation is about a user taking a break from oral minoxidil due to persistent eye puffiness after two years of use. Suggestions include switching to topical minoxidil foam and adjusting the dosage to manage side effects.

Minoxidil initially showed great results for hair loss but plateaued, leading to the addition of finasteride and dutasteride. The user is considering restarting minoxidil and is concerned about its long-term effects on skin.

RU58841 is being considered for hair maintenance by someone who can't tolerate finasteride. Alternatives like topical finasteride, dutasteride, and KX826 are also suggested.

The user experienced increased hair shedding after switching from finasteride to dutasteride, despite lifestyle improvements and additional treatments like oral minoxidil and PRP. They are concerned about persistent shedding, changes in hormone levels, and potential chronic telogen effluvium, and are considering a scalp biopsy for further investigation.

The user stopped using minoxidil due to scalp issues and switched to finasteride, noticing thicker hair initially but experiencing hair loss again. They are considering restarting minoxidil but are concerned about the shedding phase, especially with upcoming vacation plans and a potential second hair transplant.

Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.

The conversation discusses preventative hair care measures for hair loss, focusing on non-prescription treatments like rosemary, peppermint, castor oils, microneedling, and ketoconazole shampoo. It also touches on the use of finasteride, minoxidil, and RU58841 for those experiencing hair loss.

PP405 is expected to be a promising addition to hair loss treatments, potentially working well with existing treatments like finasteride and minoxidil, but not as a standalone solution. Users are hopeful for its effectiveness, especially in combination with other treatments, though expectations vary.

The user stopped finasteride for three months to try for a baby but continued using minoxidil and micro-needling. They are concerned about hair shedding and plan to resume finasteride after the baby is born.

The user has been using RU58841 for 6 months without noticeable results and is considering dropping it while continuing oral minoxidil, daily dutasteride, and topical minoxidil. Another user suggests visiting a dermatologist to check for other conditions.

Topical finasteride with minoxidil effectively stabilized and thickened hair but caused side effects like brain fog, reduced libido, and emotional flattening, leading to discontinuation. The user switched to a new regimen including minoxidil, KX-826, and other treatments, noting improvements in libido and vivid dreams after stopping finasteride.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

Minoxidil-dependent hairs fall out if minoxidil is stopped. New treatments like GT20029, FOL055, or TDM105795 might help sustain these hairs.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.